IL4 and psoriasis: Peripheral Type 1 deviation previously observed in psoriasis [3] seems to be largely corrected through alefacept administration, as Type 1 T cells are significantly reduced at week 13, but Type 2 (IL-4 producing) T cells are comparatively unaffected (Fig. 1).